Cybin to Present EMBARK Study Data at ASCP Meeting
Ticker: HELP · Form: 6-K · Filed: Apr 18, 2024 · CIK: 1833141
| Field | Detail |
|---|---|
| Company | Cybin INC. (HELP) |
| Form Type | 6-K |
| Filed Date | Apr 18, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: clinical-trial-data, pharmaceutical, conference-presentation
TL;DR
Cybin presenting Phase 2 depression drug data at ASCP meeting April 18.
AI Summary
On April 18, 2024, Cybin Inc. filed a Form 6-K report. This filing includes a news release dated April 18, 2024, announcing Cybin's participation in the 2024 Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP). The company will present data from its Phase 2 EMBARK study of CYB003, a deuterated psilocybin analog, for the treatment of major depressive disorder.
Why It Matters
The presentation of Phase 2 data for CYB003 at a key scientific conference could provide crucial insights into the drug's efficacy and safety, potentially impacting investor sentiment and future development plans.
Risk Assessment
Risk Level: medium — The filing itself is routine, but the underlying clinical trial data presentation carries inherent risks related to study outcomes and regulatory approval.
Key Players & Entities
- Cybin Inc. (company) — Registrant
- Doug Drysdale (person) — Chief Executive Officer
- April 18, 2024 (date) — Filing and News Release Date
- CYB003 (drug) — Deuterated psilocybin analog
- American Society of Clinical Psychopharmacology (ASCP) (company) — Conference
FAQ
What is the specific date of the news release included in this 6-K filing?
The news release is dated April 18, 2024.
What is the primary purpose of Cybin Inc.'s participation in the 2024 ASCP Annual Meeting?
Cybin Inc. will present data from its Phase 2 EMBARK study of CYB003.
What condition is CYB003 being studied for in the EMBARK study?
CYB003 is being studied for the treatment of major depressive disorder.
Who signed this Form 6-K filing on behalf of Cybin Inc.?
Doug Drysdale, Chief Executive Officer, signed the filing.
What is the SEC file number for Cybin Inc.'s reporting?
The SEC file number is 001-40673.
Filing Stats: 147 words · 1 min read · ~1 pages · Grade level 10.4 · Accepted 2024-04-18 15:12:44
Filing Documents
- cybininc-form6xk04x18x2024.htm (6-K) — 11KB
- a04-18x2024jmedchempublica.htm (EX-99.1) — 21KB
- image_0.jpg (GRAPHIC) — 25KB
- 0001628280-24-016744.txt ( ) — 66KB
From the Filing
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2024. Commission File Number 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CYBIN INC. (Registrant) Date April 18, 2024 By s Doug Drysdale Name Doug Drysdale Title Chief Executive Officer EXHIBIT INDEX 99.1 News Release dated April 18, 2024